CN115666551A - 通过施用树脂毒素治疗与covid-19相关的肺部炎性疾病 - Google Patents

通过施用树脂毒素治疗与covid-19相关的肺部炎性疾病 Download PDF

Info

Publication number
CN115666551A
CN115666551A CN202180025683.4A CN202180025683A CN115666551A CN 115666551 A CN115666551 A CN 115666551A CN 202180025683 A CN202180025683 A CN 202180025683A CN 115666551 A CN115666551 A CN 115666551A
Authority
CN
China
Prior art keywords
rtx
composition
pulmonary
inflammatory disease
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025683.4A
Other languages
English (en)
Chinese (zh)
Inventor
亚历西斯·拿哈马
H·H·吉
欧文·H·朱克
王汉军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorento Pharmaceutical Co ltd
University of Nebraska System
Original Assignee
Sorento Pharmaceutical Co ltd
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorento Pharmaceutical Co ltd, University of Nebraska System filed Critical Sorento Pharmaceutical Co ltd
Publication of CN115666551A publication Critical patent/CN115666551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180025683.4A 2020-03-30 2021-03-12 通过施用树脂毒素治疗与covid-19相关的肺部炎性疾病 Pending CN115666551A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002165P 2020-03-30 2020-03-30
US63/002,165 2020-03-30
US202063122858P 2020-12-08 2020-12-08
US63/122,858 2020-12-08
PCT/US2021/022089 WO2021202084A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
CN115666551A true CN115666551A (zh) 2023-01-31

Family

ID=75340289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025683.4A Pending CN115666551A (zh) 2020-03-30 2021-03-12 通过施用树脂毒素治疗与covid-19相关的肺部炎性疾病

Country Status (8)

Country Link
US (1) US20230143545A1 (https=)
EP (1) EP4125871A1 (https=)
JP (2) JP2023519853A (https=)
KR (1) KR20220161423A (https=)
CN (1) CN115666551A (https=)
AU (1) AU2021248861A1 (https=)
CA (1) CA3173611A1 (https=)
WO (1) WO2021202084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300072A (en) * 2020-08-11 2023-03-01 Sorrento Therapeutics Inc Treatment of pneumonia by nerve ablation
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
EP3131541A4 (en) * 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
US20200129472A1 (en) * 2017-02-09 2020-04-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease
MX2020002692A (es) * 2017-09-11 2020-10-14 Sorrento Therapeutics Inc Formulacion de resiniferatoxina.

Also Published As

Publication number Publication date
EP4125871A1 (en) 2023-02-08
CA3173611A1 (en) 2021-10-07
JP2023519853A (ja) 2023-05-15
US20230143545A1 (en) 2023-05-11
AU2021248861A1 (en) 2022-10-13
WO2021202084A1 (en) 2021-10-07
JP2026042884A (ja) 2026-03-11
KR20220161423A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
JP2026042884A (ja) レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置
Chaney Side effects of intrathecal and epidural opioids
ES2905425T3 (es) Composición farmacéutica de nanopartículas de docetaxel-albúmina, método de preparación de la misma y uso de la misma
US20230301700A1 (en) Treating Pulmonary Inflammatory Disease by Neural Ablation
Nicácio et al. Comparison of intraperitoneal ropivacaine and ropivacaine–dexmedetomidine for postoperative analgesia in cats undergoing ovariohysterectomy
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
Taxini et al. Control of the central chemoreflex by A5 noradrenergic neurons in rats
Keegan et al. Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism
Morris Pharmacologic aids to intubation and the rapid sequence induction
KR20100136494A (ko) 아포에쿼린 함유 조성물 및 이의 사용 방법
EP3813869B1 (en) Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation
US20200054581A1 (en) Application of trpm7 inhibitors to treat sleep apnea and hypertension in obesity
US9603843B2 (en) Kits and methods for treating post traumatic stress disorder (PTSD) and hot flashes
Khatavkar et al. The efficacy of ropivacaine-fentanyl versus ropivacaine-clonidine for pre-emptive caudal anesthesia in children
US20190076501A1 (en) Oxytocin improves treatment of obstructive sleep apnea
CN104055780A (zh) 大鼠用复方麻醉剂及其制备方法
ES2973546T3 (es) Ester isopropílico de ácido [((1R,2S,5R)-2-isopropil-5-metil-ciclohexanocarbonil)-amino]-acético para el tratamiento de la tos crónica
Akcaboy et al. Can ephedrine pretreatment be effective in alleviating rocuronium injection pain?
KR20140015150A (ko) 급성 악화성 천식의 치료 및 이로부터 고통받는 환자의 입원 가능성의 감소
KR102410183B1 (ko) 이소글리시리진산 또는 이의 염의 흡입용 제제, 및 호흡 기관 질환을 치료하기 위한 약물의 제조에서의 용도
Mohapatra et al. A study of changes in stress factors during elective upper abdominal surgery using different anaesthetic techniques
Swetha A Comparative Clinical Study of Intravenous Esmolol and Nitroglycerin for Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation in Patients Undergoing Elective Surgery
US20240415859A1 (en) Use of isorhoifolin and derivative thereof in promoting nerve repair
NO Efficacy of varying time intervals between Fentanyl and propofol administration on Propofol requirement for inducton of Anaesthesia a one year randomized control Trial
Shaikh et al. Steroids in Anaesthetic Practice-Review Article

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination